A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：2

作者：

Phillips, Tycel J. ^{[1
]}

Salles, Gilles ^{[2
]}

Landsburg, Daniel J. ^{[3
]}

Gritti, Giuseppe ^{[4
]}

Patel, Krish ^{[5
]}

Tilly, Herve ^{[6
,7
]}

Thieblemont, Catherine ^{[8
]}

Townsend, William ^{[9
]}

Ferrari, Silvia ^{[4
]}

Stumpo, Kate F. ^{[10
]}

Katyayan, Shilpi ^{[10
,11
]}

Li, Cheryl ^{[10
]}

Miao, Harry ^{[10
]}

Proscurshim, Igor ^{[10
]}

Gopal, Ajay K. ^{[12
]}

机构：

[1] Univ Michigan, Reg Canc Ctr, Ann Arbor, MI 48109 USA

[2] Univ Lyon, Lyon Sud Hosp, Lyon, France

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Osped Papa Giovanni XXIII, Hematol & Bone Marrow Transplant Unit, Bergamo, Italy

[5] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[6] Ctr Henri Becquerel, Dept Haematol, Rouen, France

[7] Ctr Henri Becquerel, INSERM 1245, Rouen, France

[8] St Louis Univ Hosp, Div Hematooncol, Paris, France

[9] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[10] Millennium Pharmaceut Inc, Cambridge, MA USA

[11] Cytel Inc, Cambridge, MA USA

[12] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Div Med Oncol,Dept Med, Seattle, WA 98195 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-125650

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5310

引用

页数：5

共 50 条

[1] Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Gordon, Leo, I
Kaplan, Jason B.
Popat, Rakesh
Burris, Howard A.
Ferrari, Silvia
Madan, Sumit
Patel, Manish R.
Gritti, Giuseppe
El-Sharkawi, Dima
Chau, Ian
Radford, John A.
de Oteyza, Jaime Perez
Zinzani, Pier Luigi
Iyer, Swaminathan
Townsend, William
Karmali, Reem
Miao, Harry
Proscurshim, Igor
Wang, Shining
Wu, Yujun
Stumpo, Kate
Shou, Yaping
Carpio, Cecilia
Bosch, Francesc
CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3546 - 3556
[2] A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Pratz, Keith W.
Kaplan, Jason
Levy, Moshe
Bixby, Dale
Burke, Patrick W.
Erba, Harry
Wise-Draper, Trisha M.
Roboz, Gail J.
Papadantonakis, Nikolaos
Rajkhowa, Trivikram
Hernandez, Daniela
Dobler, Iwona
Gregory, Richard C.
Li, Cheryl
Wang, Shining
Stumpo, Kate
Kannan, Karuppiah
Miao, Harry
Levis, Mark
HAEMATOLOGICA, 2023, 108 (03) : 705 - 716
[3] a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)
Kaplan, Jason B.
Bixby, Dale L.
Morris, John C.
Frankfurt, Olga
Altman, Jessica
Wise-Draper, Trisha
Burke, Patrick W.
Collins, Sabrina
Kannan, Karuppiah
Wang, Ling
Faucette, Stephanie
Lee, Benjamin
Shou, Yaping
Levis, Mark J.
Pratz, Keith W.
BLOOD, 2016, 128 (22)
[4] A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)
Pratz, Keith
Levis, Mark J.
Morris, John C.
Wise-Draper, Trisha
Levy, Moshe
Bixby, Dale L.
Burke, Patrick
Hernandez, Daniela
Stumpo, Kate
Kannan, Karuppiah
Sheldon-Waniga, Emily
Wang, Shining
Zhang, Steven
Shou, Yaping
Altman, Jessica K.
Kaplan, Jason
Frankfurt, Olga
BLOOD, 2017, 130
[5] Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts
Kaplan, Jason
Gordon, Leo I.
Rambaldi, Alessandro
Gritti, Giuseppe
Popat, Rakesh
Burris, Howard A.
Patel, Manish R.
Madan, Sumit
Chau, Ian
Radford, John A.
Iyer, Swami P.
De Oteyza, Jaime Perez
Zinzani, Pier Luigi
Wang, Shining
Sheldon-Waniga, Emily
Stumpo, Kate
Shou, Yaping
Carpio, Cecilia
Bosch, Francesc
BLOOD, 2017, 130
[6] POPULATION PHARMACOKINETICS OF TAK-659, AN INVESTIGATIONAL DUAL INHIBITOR OF SYK AND FLT-3, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS.
Wang, S.
Xiong, Y.
Diderichsen, P. M.
Miao, H.
Venkatakrishnan, K.
Gupta, N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S115 - S115
[7] In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts
Hughes, Keira
Evans, Kathryn
Earley, Eric J.
Smith, Christopher M.
Erickson, Stephen W.
Stearns, Tim
Philip, Vivek M.
Neuhauser, Steven B.
Chuang, Jeffrey H.
Jocoy, Emily L.
Bult, Carol J.
Teicher, Beverly A.
Smith, Malcolm A.
Lock, Richard B.
PEDIATRIC BLOOD & CANCER, 2023, 70 (09)
[8] Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies
Kaplan, Jason B.
Gordon, Leo I.
Infante, Jeffrey R.
Popat, Rakesh
Rambaldi, Alessandro
Madan, Sumit
Patel, Manish R.
Gritti, Giuseppe
Ng, Chin-Hin
Chau, Ian
Radford, John A.
de Oteyza, Jaime Perez
Zinzani, Pier Luigi
Faucette, Stephanie
Sheldon-Waniga, Emily
Williams, Miguel
Stumpo, Kate
Shou, Yaping
Carpio, Cecilia
Bosch, Francesc
BLOOD, 2016, 128 (22)
[9] Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma
Karmali, Reem
Ma, Shuo
Foster, Kelly D.
Kaplan, Jason
Palmer, Brett Alan
Mi, Xinlei
Pro, Barbara
Winter, Jane N.
Gordon, Leo I.
BLOOD, 2021, 138
[10] Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies
Petrich, Adam M.
Gordon, Leo I.
Infante, Jeffrey R.
Madan, Sumit
Giles, Francis J.
Nimeiri, Halla S.
Kaplan, Jason B.
Stumpo, Kate
Zhang, Bin
Faucette, Stephanie
Shou, Yaping
Shih, Kent C.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →